How to approach castration-resistant prostate cancer? | Zendy

Sevil Bavbek | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

How to approach castration-resistant prostate cancer?

Author(s) -

Sevil Bavbek

Publication year - 2015

Publication title -

marmara medical journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.112

H-Index - 11

ISSN - 1309-9469

DOI - 10.5472/mmj.80248

Subject(s) - medicine , castration , prostate cancer , mitoxantrone , oncology , immunotherapy , prednisone , cabazitaxel , hormonal therapy , chemotherapy , cancer , enzalutamide , hormone , androgen deprivation therapy , androgen receptor

The therapeutic landscape of castration-resistant prostate cancer (CRPC) has changed dramatically in the last decade. Previously, limited to castration, second-line hormonal manipulations, and palliative treatment with mitoxantrone plus prednisone, median overall survival (OS) remained in the 9-18 months range. With multiple lines of survival improving chemotherapies, AR-directed drugs, as well as new immunotherapy and bone-directed therapies, median OS increased to more than 30 months and quality of life increased accordingly. The question remains, as how to sequence, and choose the best therapeutic option for each individual patient with the current data. Keywords: Prostatic neoplasms, Castration-resistant, Immunotherapy, Chemotherapy, Antineoplastic agents, Hormonal, Radioimmunotherapy

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research